More precise and biologically relevant biomarkers can be achieved by using data-driven CD3<sup>+</sup>/CD8<sup>+</sup> density cutoffs and ratios, while controlling for important clinicopathologic and molecular variables in CRC. Here, CD8A is linked to colorectal carcinoma.